Home>Topics>Finance>Cantor Fitzgerald

Cantor Fitzgerald

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
  1. Syneron Medical's CEO Discusses FDA Clearance of the UltraShape System - Conference Call Transcript

    Headlines

    Thu, 17 Apr 2014

    President of Clinical and Regulatory Affairs Analyst Rich S. Newitter – Leerink Partners LLC Jeremy Feffer – Cantor Fitzgerald Anthony Vendetti – Maxim Group Zack R. Ajzenman – Griffin Securities, Inc. William J. Plovanic – Canaccord

  2. Potash Corp.: Improved Potash Prices And Dividend Growth To Drive Upside

    Headlines

    Fri, 11 Apr 2014

    dividend growth prospects. There have been multiple signs that the global potash market is stabilizing. According to Cantor Fitzgerald , the potash price in Brazil has been improving since early 2014 when it was at just $310 per tonne. The price

  3. IPO Preview: Phibro Animal Health

    Headlines

    Fri, 11 Apr 2014

    managers: BofA Merrill Lynch, Morgan Stanley, Barclays Co-Managers: Guggenheim Securities, Macquarie Capital, Cantor Fitzgerald End of lockup (180 days): Wednesday, October 8, 2014 End of 25-day quiet period: Tuesday, May 6, 2014 Summary

  4. Apple: Already Too Late To The Phablet Market

    Headlines

    Tue, 8 Apr 2014

    media predictions and rumors suggests that Apple plans to introduce larger screen phones with the iPhone 6. Even the Cantor Fitzgerald analyst gleaned bullish demand in China from consumers and carriers alike. It appears unlikely to us that Apple

  5. IPO Preview: Applied Genetic Technologies

    Headlines

    Thu, 27 Mar 2014

    at IPOpremium . SEC Documents Manager, Joint managers: BMO Capital Markets and Wedbush PacGrow Co-Managers: Cantor Fitzgerald , Roth Capital End of lockup (180 days): Tuesday, September 23, 2014 End of 25-day quiet period: Monday

  6. Avoid Applied Genetic Technologies IPO

    Headlines

    Wed, 26 Mar 2014

    filed on January 10, 2014. Lead Underwriters: BMO Capital Markets Corp, Wedbush Securities Inc Underwriters: Cantor Fitzgerald and Co, Roth Capital Partners Inc Summary AGTC is a clinical-stage biotech firm, using a proprietary gene therapy

  7. Evoke Pharma's CEO Discusses Q4 2013 Results - Earnings Call Transcript

    Headlines

    Tue, 25 Mar 2014

    Evoke Pharma, Inc. ( EVOK ) Q4 2013 Earnings Conference Call March 25, 2014 16:30 ET Executives David Burke - Investor Relations, The Ruth Group Dave Gonyer - Chief Executive Officer Matt D'Onofrio - Chief Business Officer Analysts Irina Rivkind Koffler - Cantor Fitzgerald Kay Nakae - Ascendiant ...

  8. TrovaGene's CEO Discusses Q4 2013 Results - Earnings Call Transcript

    Headlines

    Mon, 17 Mar 2014

    Officer Tony Schuh - Chief Executive Officer Dr. Mark Erlander - Chief Scientific Officer Analysts Sung Ji Nam - Cantor Fitzgerald Yi Chen - Aegis Capital Presentation Operator Good day, everyone and welcome to the TrovaGene Fourth Quarter and

  9. Summit Hotel Properties' CEO Discusses Q4 2013 Results - Earnings Call Transcript

    Headlines

    Mon, 17 Mar 2014

    Stuart Becker – EVP and CFO Analysts Ryan Meliker – MLV & Co Chris Woronka – Deutsche Bank Gaurav Mehta – Cantor Fitzgerald David Loeb – Baird Wes Golladay – RBC Capital Markets Jon Evans – JWest LLC Presentation Operator Good day

  10. Different opinions on Oncothyreon

    Headlines

    Fri, 14 Mar 2014

    Cantor Fitzgerald downgrades Oncothyreon ( ONTY ) from Buy to Hold citing valuation. Yesterday's close of $3.89 near its price target of

« Prev12345Next »
Content Partners